Acid Related Disorders Therapeutics
1. Aciphex patent expiration
Treatment: Treatment of peptic ulcers
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5045552 | WAYLIS THERAP | Pyridine derivatives having anti-ulcerative activity |
May, 2013
(12 years ago) | |
|
US5045552 (Pediatric) | WAYLIS THERAP | Pyridine derivatives having anti-ulcerative activity |
Nov, 2013
(12 years ago) | |
Drugs and Companies using RABEPRAZOLE SODIUM ingredient
Market Authorisation Date: 29 May, 2002
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of ACIPHEX before it's drug patent expiration?
More Information on Dosage
ACIPHEX family patents
2. Protonix patent expiration
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
PROTONIX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5997903 | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Dec, 2016
(9 years ago) | |
|
US5997903 (Pediatric) | WYETH PHARMS | Oral-administration forms of a medicament containing pantoprazol |
Jun, 2017
(8 years ago) | |
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months ago) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months ago) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 3 months ago) | |
| US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(4 months from now) | |
|
US7544370 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(10 months from now) | |
|
US7550153 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(9 months ago) | |
|
US7553498 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(9 months ago) | |
|
US7838027 (Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 12 June, 2001
Dosage: FOR SUSPENSION, DELAYED RELEASE; TABLET, DELAYED RELEASE
How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage
PROTONIX family patents